- October 21, 2019
MTI Secures $4.2M Financing Round
MTI announced a $4.2M raise. The company's lead product, PolypDx™, is the world's first and only urine test for colorectal cancer screening. Developed in Canada, and patented globally, PolypDx™ is currently being assessed by the Alberta provincial health system in Canada as a way to increase overall screening efforts to help manage the disease of colorectal cancer. The next critical step to bring MTI's innovative test to patients, is a multi-centre pivotal trial in the US. Evidence generated from the trial will provide the basis for a commercial launch, clinical acceptance and reminbursement of PolypDx™.
- September 25, 2019
MTI Named BioAlberta Company of the Year
MTI was presented with the BioAlberta Company of the Year Award at the 20th Annual BioAlberta Awards Gala last night. This Award was presented to MTI for excellence and innovation with their flagship product, PolypDx™, and their strong performance and leadership role in the Alberta business community. MTI was presented the award by Bob Dawson, Senior Manager, Patient Access and Health Policy, from Pfizer Canada.
- May 27, 2019
DynaLIFE Accelerator Lab welcomes new partner and leading-edge cancer screening technology in Edmonton
DynaLIFE and Metabolomic Technologies Inc. (MTI) today unveiled a new state-of-the-art clinical space in Edmonton enabling the assessment of an innovative new test for Albertans in the detection and prevention of colorectal cancer, the second most commonly diagnosed cancer in Canada and the second and third leading cause of cancer-related deaths for men and women. "Over the past few months, DynaLIFE has been working closely with MTI and their flagship product, PolypDx™ with the aim to provide doctors with this exceptional new tool for early screening and detection enabling the timely removal of polyps before they progress to colorectal cancer," says Jason Pincock, Chief Executive Officer of DynaLIFE. "Partnering with MTI was a natural fit for DynaLIFE as we immediately recognized the value of incorporating this innovative diagnostic technology."
- October 22, 2018
Alberta to assess a new screening strategy using MTI's PolypDx™
Metabolomic Technologies Inc. (MTI) today announced the launch of a $1.4 million project that will evaluate a new colorectal cancer screening strategy using PolypDx™, the first and only urine test for the detection and prevention of colorectal cancer. The project, called the Canadian Assessment of PolypDx™ (CAP), will engage expert physicians, clinicians, patients and laboratory specialists to assess colorectal cancer screening in 3000 patients in five regions located throughout Alberta.
- October 7-10, 2018
MTI to Exhibit at ACG - October 7-10 in Philadelphia
MTI is excited to be attending the 2018 American College of Gastroenterology Conference in Philadelphia, PA. Team members will be on site ready to discuss the first and only urine test for detection and prevention of colorectal cancer, PolypDx™. Come check us out at Booth #1237 in the Exhibit Hall!
- November 8, 2017
MTI selected to present at Falling Walls Venture in Berlin, Germany
Metabolomic Technologies Inc. is selected as one of 20 outstanding science based start-ups from leading international academic institutions and international venture capitalists in the Falling Walls Venture competition held in Berlin, Germany. As a finalist for the competition, Dr. Chang presented MTI's easy-to-use test for the screening and prevention of colorectal cancer to a gathering of science based start-ups, investors and opinion leaders at the British Embassy in Berlin.
- November 1, 2017
Patent Granted for PolypDx™ in Europe
Metabolomic Technologies Inc. has been granted a patent for its PolypDx™ technology by the European Patent Office. PolypDx™ received patent approval in Japan in September, 2015, and in Australia in February, 2017. Patents are also pending in the US, Canada and Hong Kong.
- June 21, 2017
MTI Appoints David Chang as New CEO
Metabolomic Technologies Inc. announces that it has appointed David Chang as Chief Executive Officer as of May 1st, 2017. Dr. Chang replaces Reg Joseph as CEO. He brings to the position 15 years experience managing SMEs and commercializing research projects. As the previous Chief Operating Officer of MTI, Dr. Chang oversaw the development of PolypDx™ from the research lab to market, and has established MTI as a respected and award-winning innovator.
- June 6, 2017
MTI Recipient of the 2017 ATB Catalyst Export Award
On June 6, 2017 MTI was presented with the 2017 ATB Catalyst Export Award. The award recognizes MTI's engagement in international business and export, while achieving excellence through sustainable growth and innovation.
- May 5, 2017
MTI Launches New Product Website - PolypDx.com
MTI is pleased to announce the launch of a new product website for our flagship product, PolypDx™. This website will provide important education and information on PolypDx™ for both patients and healthcare professionals, as we expand coverage of PolypDx™ in the US and worldwide.
- May 6 to 9, 2017
MTI to Exhibit at DDW - May 2017 in Chicago, IL
MTI is excited to be attending the 2017 Digestive Disease Week Conference, May, 2017 in Chicago, IL. Team members will be on site ready to discuss our non-invasive urine-based diagnostic test for detection of adenomatous polyps, PolypDx™. Come check us out at Booth #1612 in the New Exhibitor Pavillion Area!
- March 25, 2017
MTI's Chief Operating Officer, Dr. David Chang - 2017 Canadian Medtech Mission to China
From March 20 to 23, 2017, MTI's Dr. David Chang travelled to Beijing and Tianjin, China, as part of a delegation of medical device companies from Canada. PolypDx™ was featured as a leading potential diagnostic for the Chinese market. The Canadian mission was highlighted in this Beijing news piece on March 23, 2017 - Canadian Medical Companies Visit Beijing.
- February 9, 2017
MTI Granted Patent for PolypDx™ in Australia
In early February, 2017, Metabolomic Technologies Inc. was granted a patent for its PolypDx™ technology by the Australian Patent Office. PolypDx™ received patent approval in Japan in September, 2015. Patents are also pending in the US, Canada, and Europe.
- January 23, 2017
MTI Signs Muti-Year, Non-Exclusive Licensing and Distribution Agreement with U.S. Based Evolution Laboratories in Association with Lab Express, LLC
MTI has signed a multi-year, non-exclusive licensing and distribution agreement with U.S. based Evolution Laboratories for its flagship product, PolypDx™, a urine-based diagnostic test for detection of adenomatous polyps, the precursor to colorectal cancer. This agreement marks the second licensing and distribution secured by MTI in the last year. The non-exclusive licensing and distribution agreement signed between MTI and Evolution Laboratories in association with Lab Express, LLC, provides additional entry points into five western U.S. states including; Nevada, California, Arizona, Utah and Texas.
- June 27, 2016
Atlantic Diagnostic Laboratories Launches Revolutionary Urine-Based Diagnostic Test to Detect Precursor to Colon Cancer
Atlantic Diagnostic Laboratories (ADL), today announced the official launch of PolypDx™, a non-invasive urine-based diagnostic test for detection of adenomatous polyps, the precurser to colorectal cancer. "ADL, with it's extensive LC/MS/MS expertise, is very excited to be offering the PolypDx™ non-invasive urine test for its official launch into America," said Aaron Domenico, Chief Operating Officer of ADL. "Colorectal cancer is a leading cause of death in the United States. With early detection in the adenamatous polyp stage, this form of cancer is preventable."
- December 18, 2015
MTI to Exhibit at MSACL February 2016 in Palm Springs
MTI is excited to be attending the 2016 Mass Spectrometry: Application to the Clinical Lab (MSACL) Conference, February, 2016 in Palm Springs, CA. Team members will be on site ready to discuss the future of metabolomics in health care and our flagship product, PolypDx. Come check us out at Booth #16!
- January 22, 2015
MTI to be commercial arm of new Metabolomics Technology Demonstration Center
- November 20, 2014
Colon Cancer News Today
- November 19, 2014
Becker’s Healthcare G/I & Endoscopy News
- November 19, 2014
BioAlbertaSpotlight : MTI Highlighted by BioAlberta
- November 12, 2014
San Francisco Business Times
- November 12, 2014
Frost & Sullivan Recognizes MTI’s Revolutionary PolypDx, a Screening Test for Early Indication of Colorectal Cancer.
- September, 2014
MTI travels to China for clinical trial and new business opportunities.
Dr. Richard Fedorak and Mr. Reg Joseph visited our collaborative partner, BGI-Shenzhen in Shenzhen, Guangdong province as we enter the next phase of our clinical trial. This is a validation study of our flagship product, PolypDx™, a non-invasive, urine test that detects individuals who have the precursors to colorectal cancer. By testing our product in a different ethnic population than Alberta, we will be able to...
- May 2-6, 2014
MTI Exhibitor at Annual SGNA Conference in Nashville
MTI was invited to be an Exhibitor at the 41st annual Society of Gastroenterology Nurses and Associates(SGNA) conference in Nashville, TN. The conference promotes education and highlights advances in clinical gastroenterology. Attended primarily by Americans and Europeans, this opportunity saw MTI developing an...
- January 2, 2014
Career Opportunities: Project Assistant
Update: This position has been filled.
- December 1, 2013
Enhancing colon cancer screening through polyp detection
Genetic Engineering & Biotechnology News (GEN), the number one biotech publisher around the globe since its launch in 1981, published a corporate profile on MTI and our non-invasive urine test that detects precancerous polyps (the precursor to colorectal cancer). Please see more details at GEN.
- November 28, 2013
Diagnosing colonic polyps: an interview with Dr. Haili Wang, MTI
An interview with Dr. Haili Wang, colorectal surgeon and Chief Scientific Officer at MTI, was highlighted by News Medical. News Medical, owned and operated by AzoNetwork, is an online publisher of science and engineering websites and online scientific journals that receives over 5 million visits each month, majority of which are from North America. See more details at News Medical.
- October 25, 2013
A test for targeting colonoscopies? Yes please.
The Fall 2013 Edition of Health Solutions, a magazine published by Alberta Innovates-Health Solutions that features stories of health research, health care and health promotions, highlighted MTI's test that uses "compounds in the urine to help find individuals with pre-cancerous colonic polyps so they can be prioritized for further testing".
- October 15, 2013
MTI develops next generation diagnostic platform with Alberta partners
MTI was recently named the recipient of a $250,000 industrial research grant through the National Research Council of Canada Industrial Research Assistance Program. The grant will support the commercialization of PolypDx™ (a diagnostic test for pre-cancerous polyps) as MTI continues to collaborate with Alberta partners, including Alberta Innovates Center for Machine Learning and The Metabolomics Innovation Center.
- October 10, 2013
MTI is the recipient of the University of Alberta's Spin-off Achievement Award
Hosted by TEC Edmonton, "Innovation...Makes Sense" celebrates the ongoing translation of local research and innovation into valuable technologies and products. The event recognized two of the most promising recent spin-off companies created from research conducted at the University of Alberta, one of which was MTI. Please see more details at Metro.
- August 21, 2013
Cancer screening tech on its way to commercialization
MTI was highlighted in Metro, Canada's most read national daily newspaper brand (1.6 million readers daily on print, 565,000 monthly unique visitors on mobile, and 1.6 million monthly unique visitors on the web) and the first daily to publish in both official languages.
- August 20, 2013
University of Alberta highlights MTI's new cancer screening technology
A colon cancer screening test developed at the University of Alberta is on its way to commercialization and potential worldwide use, through a new collaboration with a leading Chinese research institute and MTI.
- August 15, 2013
MTI highlighted in a TEC Edmonton press conference announcing its positive impact on startups
TEC Edmonton released survey results that confirms its positive impact on startups, and highlighted MTI as one of the company it has helped to grow faster.
- August 12, 2013
University of Alberta metabolomics research team collaborates with prestigious BGI Shenzhen on new cancer screening technology.
MTI's diagnostic test for pre-cancerous polyps, PolypDx™, is moving towards commercialization thanks to collaboration between the Alberta government, the University of Alberta, the renowned BGI Shenzhen (formerly Beijing Genomic Institute) and MTI.
Please see more details at Morningstar, or at Biotechnology Focus.
- July 25, 2013
MTI acknowledged in international incubator study highlighting TEC Edmonton.
TEC Edmonton has been named one of the world's top university business incubators and acknowledged MTI as one of the companies it has helped spin-off from the University.
- June 6, 2013
PolypDx™ is a vehicle for Alberta medical research multi-partner eco-system.
- May 15, 2013
Alberta Innovates - Health Solutions awards $375,000 to develop new colon cancer screening test by Metabolomic Technologies Inc.
MTI was recently named the recipient of a Knowledge Translation Strategic Initiative Grant by Alberta Innovates - Health Solutions in the amount of $375,000 through the Alberta Cancer Prevention Legacy Fund. This new funding will support validation trials for MTI's patented colonic polyp (polyps can be precursors to colon cancer) screening diagnostics test, PolypDx™.
Please see more details at Wall Street Journal, or at Yahoo! Canada.
- April, 2013
Simple New Test to Prevent Colon Cancer
- March, 2013
Enhanced Diagnostics Testing Through Metabolomics article published in ANZMAGazine.
Expanding MTI's global reach, ANZMAGazine is out of Australia and New Zealand with a community of researchers working in magnetic resonance fields.
- March 25, 2013
AlHS Strategic Initiative Grant awards MTI $375,000.
MTI has received R&D financial support from Alberta Innovates - Health Solutions through the Alberta Cancer Prevention Legacy Fund (ACPLF). The project: Validation Trials of Two Novel Patented Metabolomics and Urine Based Colorectal Polyp and Cancer Screening and Diagnostics Tests - PolypDx™ and ColoDx™ will support development in "real-life" clinical environments.
- March 20, 2013
MTI's work in China gets financial support from Alberta's government.
MTI has been awarded $200,000 from the Alberta Enterprise and Advanced Education (EAE) program to support the collaboration trials in China.
- March, 2013
MTI travels to Shanghai, China to continue collaborations with BGI and CDC.
MTI made a second trip to China to continue the collaboration project plans. The originally selected hospital in Hangzhou was unable to meet the clinical requirements for the projected clinical trial, however thanks to BGI's forward-thinking, a new partnership has been established with the Center for Disease Control and Prevention in the Minhang District of Shanghai. The CDC has a strong community relationship and an established infrastructure to drive the planned projects to completion.
- February 26, 2013
From Idea to Commercial Success
- December 19, 2012
Alberta/Pfizer Translational Research Fund Opportunity Competition: MTI's Scientific Research team at the University of Alberta awarded $200K
This grant will fund work on identifying new biomarkers for a HTP system for better colon cancer screening. Funding for this 18-month project to commence in February, 2013.
- August 30, 2012
MTI’s Scientific Officer, Victor Tso, presents at the Wuhan Institute of Physics and Mathematics Chinese Academy of Sciences
- August, 2012
MTI travels to Hangzhou, China and meets with BGI
MTI has initiated clinical trials in China in partnership with BGI-Shenzhen. The clinical trials will take place in China’s scenic Hangzhou region and will serve 3 purposes. First to generate data in the Chinese population that will demonstrate the robustness of MTI’s tests in a distinct and relatively homogenous non Caucasian population. Secondly, in collaboration with the BGI scientific team, MTI will explore novel biomarkers for use in its next generation high throughput platform. Lastly, these trials will serve as a logistics trial in preparation for MTI’s commercial release of its PolypDx™ in China in second half of 2013.
- August 25, 2012
MTI selected to present at Banff Venture Forum
- July 5, 2012
MTI is awarded funding from the Going Global Innovation
The Going Global Innovation (GGI) component of the Global Commerce Support Program through the Foreign Affairs and International Trade Canada has approved funding towards MTI’s travel to China. MTI will work with BGI on an exciting new project: mass-spectrometry urine test development through an international partnership.
- June 20, 2012
Dr. Fedorak’s interview on Alberta Prime Time
- June 20, 2012
Reg Joseph Interviewed at Bio 2012 in Boston
- June, 2012
BGI visits Alberta and the University of Alberta BGI
Scientists (including the ones collaborating with MTI) visited the University to Alberta to share knowledge and insights and in the fields of genomics, proteomics and metabolomics. BGI is excited about the current collaboration around the development of high value diagnostics with University of Alberta metabolomics clinicians, researchers, and MTI. BGI and the University of Alberta hope to develop additional collaborations between these institutions in the future to foster ongoing scientific collaboration and commercial outcomes for our respective regions. The visit took place during the second of week June and included a visit to Jasper, Banff, and Columbia Ice fields.
- May 28, 2012
MTI secured a NSERC engage grant
MTI initiates Discovery Program for Novel Biomarkers with the University of Alberta - to initiate a collaboration with metabolomic and mass spectrometry experts at the University of Alberta to search for novel biomarker to add robustness to MTI current PolypDx™ test. This will offer more flexibility as MTI optimizes its signature for the development of its high throughput platform. MTI will primarily be collaborating with Dr. Russ Greiner. Based on early positive momentum, MTI and has applied for additional non-diluting funding to augment this discovery program.
- May 17, 2012
New urine test could prevent thousands of cancer dealths.
Edmonton Journal by Jodie Sinnema
Researchers at the University of Alberta have developed a simple urine test to detect pre-cancerous polyps in the colon that could revolutionize screening programs around the world and save thousands of lives.
- March 6, 2012
MTI wins TEC Edmonton’s 2012 Enterprise Award – Listen to full interview with CEO Reg Joseph
- February, 2012
MTI visits China’s Beijing Genomics Institute
Members of MTI travelled to Shenzhen to meet with BGI and present our exciting research. Through this visit MTI hopes to expand its research and develop a collaboration with BGI in the near future.
- May 24, 2011
(CBC News) Colon cancer screening reaches too few: report
Wider use of home screening tests for colorectal cancer could prevent unnecessary deaths, the Canadian Cancer Society says...
- May 10, 2011
(CTV.ca) Simple urine test might spot early colorectal cancer
A made-in-Canada urine test appears to be able to spot the signs of early colorectal cancer, and might eventually do away with less appealing screening methods...
- October 28, 2010
TEC Edmonton: Chemical fingerprint - clue to colon cancer
- June 18, 2010
University of Alberta: Chemical fingerprint - clue to colon cancer